RANBP9 and lung carcinoma: The observation that RanBP9 abrogation enhances the sensitivity to genotoxic treatments (IR and cisplatin) of specific lung cancer cells invites to speculate that compounds inhibiting RanBP9 activity in DDR might represent a new strategy to induce synthetic lethality.